1) Absorption, distribution and excretion of 14C-Dipyridamole (RA 8) wee studied comparatively after the administration of single intravenous (5 mg/kg), single oral (10 mg/kg) and multiple oral (10 mg/kg, once a day for one week) dosages in rats. 2) The blood level of radioactivity after oral administration showed a monophasic slow elimination with a half-life (t1/2) of about 10 hrs. The apparent absorption rate was not so high (t1/2 : 0.72 hr), therefore, it took about 3 hrs to reach the maximum level. 3) When the drug was applied intravenously, radioactivity in blood decreased tri-phasically, but the terminal phase, which appeared 12 hrs after the application, showed the same elimination rate as that of p. o. application, i.e., t1/2 : about 10 hrs. 4) The observed values of radioactivity during and after the multiple dosing regimen fitted well on the simulation curve derived from the results of a single administration. 5) Radioactivity was mainly distributed in the alimentary canal, liver and kidney, which were isolated after single or multiple oral administration. No radioactivity was found in CNS. Whole body autoradiogram obtained after intravenous or oral administration also supported the results of distribution as above. 6) No considerable accumulation of radioactivity was recognized in any tissues after the multiple dose in the rat.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2131/jts.5.339 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Can febrile neutropenia re-invent its self?
Curr Opin Oncol
January 2025
Service de Médecine Oncologique, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Bruxelles, Belgique.
Purpose Of Review: Febrile neutropenia as a complication of cytotoxic chemotherapies, remains a major event in the medical journey of hematology and oncology patients. In this review, we are trying to review the new elements and highlights that are shaping febrile neutropenia in nowadays.
Recent Findings: Introduction of risk-stratification, expanded use of granulocyte-colony stimulating factor and oral treatment for selected patients and rapid administration of antibiotics revolutionized the treatment of febrile neutropenia.
Chemotherapy-induced nausea and vomiting: can we do better?
Curr Opin Oncol
January 2025
Gustave Roussy, Villejuif, France.
Purpose Of Review: Although the management of nausea and vomiting induced by cancer treatments has evolved, several questions remain unanswered.
Recent Findings: New antiemetics have been developed these last decades with therapeutic indications to be defined according to the anticancer regimen and partly as a consequence of the assessment of individual patient risk factors. Guidelines still seem to have a low level of knowledge and compliance, with a role for scientific societies in term of dissemination and education.
New approaches in childhood IgE-mediated food allergy treatment.
Curr Opin Allergy Clin Immunol
January 2025
Translational Research in Pediatric Specialities, Division of Allergy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Purpose Of Review: This review aims to provide an overview of the current and future treatment options for children with food allergies (FAs), highlighting the latest research findings and the potential impact of these new approaches on improving patients' and caregivers' quality of life.
Recent Findings: In the last decade, many promising approaches have emerged as an alternative to the standard avoidance of the culprit food with the risk of severe accidental reactions. Desensitization through oral immunotherapy has been introduced in clinical settings as a therapeutic approach, and more recently also omalizumab.
Efficient Co-Delivery of Metformin and Ammonia Borane via a Hollow Mesoporous Polydopamine Nanogenerator for Enhanced Chemo-Photothermal Therapy against Melanoma.
ACS Appl Mater Interfaces
January 2025
School of Life Sciences, Henan University, Kaifeng, Henan 475001, China.
Melanoma, a highly aggressive skin cancer, poses significant challenges due to its rapid metastases and high mortality rates. While metformin (Met), a first-line medication for type 2 diabetes, has shown promise in inhibiting tumor growth and metastases, its clinical efficacy in cancer therapy is limited by low bioavailability, short half-life, and gastrointestinal adverse reactions associated with oral administration. In this study, we developed a hollow mesoporous polydopamine nanocomposite (HMPDA-PEG@Met@AB) coloaded with Met and ammonia borane (AB), designed to enable a combined gas-assisted, photothermal, and chemotherapeutic approach for melanoma treatment.
View Article and Find Full Text PDFAndexanet alfa: trials just leave us with more questions.
Res Pract Thromb Haemost
January 2025
Department of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom.
Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor (ANNEXA-I), the first ever randomized controlled trial of a reversal agent for direct oral anticoagulants, was published in 2024. The trial, which randomized patients with intracranial hemorrhage to andexanet alfa or usual care, was mandated by the United States Food and Drug Administration as part of its conditional approval in 2018. This approval was originally based on the single-arm trial, The Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors (ANNEXA-4).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!